Developer docs
API playgroundTry for free, no card

Search company profiles

LabCentral

Full company profile

uuid0000jay

Namestring
LabCentral
Legal namestring
Lab Central, Inc.
Websiteurl
labcentral.org
Company typeenum
Private
Founded yearint
2013
Descriptiontext

LabCentral is a 501(c)(3) nonprofit organization founded in 2013 and headquartered at 700 Main Street in Cambridge, Massachusetts. It operates a six-site network spanning approximately 243,000 square feet across Kendall Square and the Harvard University campus, providing shared, fully permitted laboratory and office infrastructure, shared equipment, and operational support to approximately 100 early-stage life sciences and biotechnology startup teams. Its core products include LabCentral 700 (flagship), LabCentral 238 (process development and scale-up), Bayer Co.Lab Cambridge, and the Harvard-affiliated Pagliuca and Blavatnik Life Labs. LabCentral's revenue comes from three primary streams: month-to-month lab and office rental fees from resident companies, tiered sponsorship payments (Gold, Platinum, General) from pharmaceutical and life sciences companies, and grants from government and nonprofit funders such as the Massachusetts Technology Collaborative.

The organization differentiates itself from a typical coworking operator through a curated ecosystem model. A network of more than 70 sponsor organizations — including Bristol Myers Squibb, Novo Nordisk, Sanofi, Daiichi Sankyo, Takeda, Lilly, Pfizer, Bayer, AbbVie, Ajinomoto, Servier, and Breakthrough T1D — funds programs such as Golden Tickets ($50,000 residency credits), the annual Ignite contest, and LabCentral First (six months of free bench space for first-time founders). LabCentral also runs the AI BioHub, a 2025-launched center of excellence co-developed with C10 Labs that combines wet lab infrastructure with AI-specific resources, a 10-week accelerator curriculum, and mentorship. Resident and alumni companies have cumulatively raised $21.85 billion in venture capital since 2013, catalyzed 7,915 jobs in Massachusetts, launched 171 clinical trials, and received 1,846 patents, with LabCentral-affiliated companies representing 10% of total US early-stage biopharma venture funding and 16% of Massachusetts early-stage funding. Recent strategic moves include international partnerships with Japan's Shonan iPark and Hong Kong's HKSTP, a 2025 CEO transition, and the addition of a Head of Science Strategy role.

Short descriptiontext

LabCentral is a nonprofit shared laboratory network operating six sites totaling 243,000 square feet in Kendall Square and Harvard, providing lab infrastructure, sponsor-funded programs, and accelerator services to approximately 100 early-stage life sciences and biotech startup teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHardwick, United States
HQ citystring
Hardwick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
shared lab facilities, biotech incubator services, life sciences infrastructure, lab coworking space, biotech startup support
Industry3 codes
1Lab Furniture, Facilities & Utilities (Benches, Casework, Gas/Water Systems)
CodeHLAGAIAMPrimaryYes
2Hands-on Science Exploration & Experiments (Lab Kits, Science Clubs)
CodeEDAMABAAPrimaryNo
3Makerspace, Innovation Lab & Fab Lab Operations (Tools, Safety, Programming)
CodeEDAEAGAIPrimaryNo
NAICS code2 codes
  • Facilities Support Services5612
  • Facilities Support Services56121
SIC code1 code
  • Laboratory Apparatus & Furniture3821
Product category
Biotech Lab Infrastructure and Incubator Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Lab and Office Space Rental
TypeSubscription Recurring
Description

LabCentral provides month-to-month, fully functional lab and office spaces, permitting, waste handling, and equipment for biological R&D. Revenue is generated from bench and office rental fees charged to resident companies. Bench rates were reduced by over 25% for 2026 to support the community.

labcentral.org
2Sponsorship Programs
TypeSubscription Recurring
Description

Pharmaceutical and life sciences companies sponsor LabCentral at Gold, Platinum, and General tiers. Sponsors gain access to the startup ecosystem, Golden Ticket programs, mentorship opportunities, and networking. Notable sponsors include Sanofi (Gold), Daiichi Sankyo (Platinum), Ajinomoto (Gold), Bristol Myers Squibb (Platinum), AbbVie, Takeda, Lilly, Pfizer, and Bayer.

morningstar.com
3Nonprofit Funding and Grants
TypeSubscription Recurring
Description

As a 501(c)(3) nonprofit, LabCentral receives grant funding from organizations like the Massachusetts Technology Collaborative (MassTech), which provided a $1.9M Sector Spark Grant for the AI BioHub.

labcentral.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D
Pricing details3 tiers
1LabCentral First - Free 6-month bench for first-time founders
ModelFreemiumBilling cadenceMulti-year contract
Notes

Eligible first-time biotech founders receive a single lab bench free of charge for 6 months. Up to 18 startups selected competitively. Targets first-time founders, new to Massachusetts, or pursuing underfunded novel science.

prnewswire.com
2Golden Ticket - $50,000 credit for residency
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Each Golden Ticket is a $50,000 credit toward space and services at LabCentral's flagship site at 700 Main Street in Cambridge, for use within a 13-month period. Awarded by pharma sponsors (Bristol Myers Squibb, Novo Nordisk, Sanofi, Daiichi Sankyo, etc.).

labcentral.org
3Standard Lab Bench and Office Space - Reduced 2026 rates
ModelSubscriptionBilling cadenceMonthly
Notes

Bench rates reduced by over 25% for 2026 to support the broader community. Month-to-month rental includes fully functional lab spaces, permitting, waste handling, and shared equipment access.

labcentral.org
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1AI BioHub
Description

AI-biotech accelerator program run in partnership with C10 Labs offering labs, curriculum, mentorship, and infrastructure for AI-first biotech startups.

labcentral.org
+7 more records
Core offering1 text field

LabCentral operates a six-site network of fully permitted, ready-to-go shared lab and office facilities in Kendall Square, Cambridge and on the Harvard campus, providing month-to-month rental of lab benches and offices to early-stage life sciences and biotech startups. The offering includes shared equipment, permitting and waste handling, operational and facilities support, and access to a curated ecosystem of sponsors, mentors, and peers. Specialized programs layered on top of the physical infrastructure include the AI BioHub accelerator, sponsor-funded Golden Tickets, and the LabCentral First program for first-time founders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • $1.25B raised by resident companies in 2025; $21.85B cumulative since 2013
+7 more records
Product overview1 text field

LabCentral is a nonprofit organization operating a network of six shared lab and office facilities across Kendall Square in Cambridge, Massachusetts and Harvard University campus, spanning over 243,000 square feet. The portfolio includes LabCentral 700 (flagship main location), LabCentral 238 (process development/scale-up), Bayer Co.Lab Cambridge, Pagliuca Harvard Life Lab, and Blavatnik Harvard Life Lab Longwood. Beyond physical lab space, LabCentral provides a comprehensive ecosystem including the AI BioHub (AI-biotech accelerator with C10 Labs), Golden Tickets ($50,000 sponsor-funded residency credits), LabCentral First (free lab space for first-time founders), Ignite Golden Tickets ($250,000 annual contest), Core Facilities network, Startup Programs, Pathway Programs (What the Heck is Biotech?, Biotech Blend X, Biotech Ready), and Gallery 1832. The organization supports early-stage life sciences companies with lab infrastructure, operational support, programming, and community to accelerate biotech innovation.

Product and service11 records
1LabCentral 700 Main Street
CategoryShared Lab Facility
Description

LabCentral's flagship site at 700 Main Street in Cambridge, MA, providing month-to-month, fully functional lab and office spaces, permitting, waste handling, and shared equipment for early-stage biotech startup R&D.

2LabCentral 238
CategoryShared Lab Facility
Description

Purpose-built facility at 238 Main Street in Cambridge, MA, designed for process development and scale-up, offering specialized infrastructure for startups advancing from discovery to larger-scale operations.

3Bayer Co.Lab Cambridge
CategoryShared Lab Facility
Description

LabCentral-managed facility with programming curated for entrepreneurs and scientists, providing access to Bayer's ecosystem and specialized biotech support.

4Pagliuca Harvard Life Lab
CategoryShared Lab Facility
Description

Harvard-affiliated biotech venture facility where Harvard-affiliated startups can access lab space and resources within the Harvard ecosystem.

5Blavatnik Harvard Life Lab
CategoryShared Lab Facility
Description

R&D facility for Harvard-affiliated pre-seed and seed ventures, providing specialized lab infrastructure for early-stage life sciences companies.

6Core Facilities Network
CategoryShared Lab Facility
Description

Premier network of core facilities providing access to specialized scientific equipment and expertise to amplify resident R&D capabilities.

7AI BioHub
CategoryAccelerator Program
Description

AI-biotech support program providing startups with labs, infrastructure, instrumentation for high-speed cell sorting, automated liquid handling, and network access to integrate artificial intelligence into biological discovery. Includes accelerator program co-led with C10 Labs.

8AI BioHub Accelerator Program
CategoryAccelerator Program
Description

10-week accelerator program providing AI-specific curriculum (Business of Biotech to Generative AI and ML Ops), wet lab access, AI Fellows mentorship, and individualized industry mentorship for early-stage AI-biotech companies. First cohort of 13 teams raised over $8M collectively.

9LabCentral First
CategorySubsidized Residency Program
Description

Program offering eligible first-time biotech founders six months of free lab space at a single bench. Targets first-time founders, new arrivals to Massachusetts, or those pursuing underfunded novel areas of science. Up to 18 startups selected competitively.

10Golden Ticket Program
CategorySponsored Residency Program
Description

Sponsor-funded residency opportunities providing selected startups with $50,000 in credits toward lab space and services at LabCentral facilities. Awarded by pharma sponsors including Bristol Myers Squibb, Novo Nordisk, Sanofi, Daiichi Sankyo, Takeda, Lilly, Pfizer, Bayer, AbbVie, and Breakthrough T1D.

11Ignite Golden Ticket Contest
CategorySponsored Residency Program
Description

Annual Golden Ticket contest awarding five $50,000 tickets totaling $250,000 in value, with winning companies receiving lab space credits plus a one-year fellowship program with expanded access to resources and networks. Co-sponsored by Bayer, Lilly, Pfizer, and Takeda.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

HKSTP signed an MOU with LabCentral for cross-border startup support as part of HKSTP's largest-ever delegation to BIO 2026 in San Diego. The partnership aims to provide Hong Kong biotech startups access to the LabCentral ecosystem and Greater Boston biotech community.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-05-20
Description

CKD Pharm held its 2026 Golden Ticket event at LabCentral in Boston, awarding the sponsorship to Arpelos Biosciences (AI-driven protein engineering for autoimmune diseases). Approximately 50 biotech startups applied, with three finalists competing. The Golden Ticket program serves as CKD Pharm's platform for identifying early-stage innovative technologies.

Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2026-02-17
Description

Sanofi joined LabCentral as a Gold Sponsor, hosting their inaugural Golden Ticket reception in January 2026. Sanofi outlined a four-pillar R&D vision (immunoscience, neuroscience, oncology, genomic medicine) and collaborative mechanisms including iAwards, Open Innovation Lab, and startup bridge programs. Sanofi will launch a Golden Ticket program and host office hours with resident startups.

Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2025-10-15
Description

Bristol Myers Squibb sponsors LabCentral's Golden Ticket program as a Platinum Sponsor. BMS evaluates and awards $50,000 credits to early-stage biotech companies working in oncology, immunology, cardiovascular disease, and neuroscience. Deck Bio and ReTrax Therapeutics were awarded 2025 BMS Golden Tickets.

5Shonan iPark (Japan)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

LabCentral partnered with Shonan iPark, Japan's first pharmaceutical-initiated science park, to offer selected Japanese startup teams a three-month residency program in Cambridge. Participants engage in executive educational programming and connect with the LabCentral ecosystem. LabCentral and Shonan iPark also co-host the Shonan Health Innovation Conference (SHIC) 2025 in Cambridge. Operated by iPark Institute Co., Ltd., backed by Takeda, IIF, and Mitsubishi Corporation.

labcentral.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

LabCentral co-hosts the Boston Biotech Investor Day (BBID) with BioLabs and The Engine, now in its second year (2025). The Termeer Institute joined as a co-host. BBID features 48 early-stage companies, 90+ investors and pharma partners, entrepreneur pitches, and poster presentations. Reinforces Massachusetts as a global life sciences leader.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-04
Description

The Termeer Institute joined as a co-host of Boston Biotech Investor Day 2025. The Termeer Institute empowers a diverse global community of life science innovators, aligning with LabCentral's mission to support the ecosystem around biotech entrepreneurs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-05
Description

Breakthrough T1D partnered with LabCentral to launch a Golden Ticket competition specifically for companies working to treat or cure type 1 diabetes. The $50,000 award is Earmarked for Disease Modifying Therapies (DMT) and Cell Therapies (CT) in T1D. This is a first-of-its-kind partnership between LabCentral and a mission-driven nonprofit.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-07-31
Description

Bayer, Lilly, Pfizer, and Takeda co-sponsor LabCentral's annual Ignite Golden Ticket contest, awarding five $50,000 tickets totaling $250,000. Each winning company also receives a one-year fellowship program with access to resources and networks. The contest is in its fifth year (2025).

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-05-28
Description

Servier expanded its Golden Ticket incubator program globally, partnering with LabCentral in Boston-Cambridge and BioLabs at Saclay in France (Spartners facility). Servier's program offers selected startups one-year incubation, lab facilities, researcher operating costs, and mentorship in oncology and neurology. LabCentral has awarded over 150 Golden Tickets worth $7.5M since 2017.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-18
Description

LabCentral and C10 Labs co-developed the AI BioHub in Kendall Square, a center of excellence for AI-native biotech startups. C10 Labs co-leads multiple AI/bio cohorts, providing AI expertise, fractional AI engineers, cloud infrastructure, and venture studio methodology. The first cohort graduated 13 teams that raised over $8M collectively. The second cohort of 16 teams began in March 2026.

Strategic tierMinorTypeOthersAnnounced on2025-03-18
Description

Anna Marie Wagner, a leader at the intersection of AI and life sciences, joined LabCentral's AI BioHub as a strategic advisor. Previously an executive at Ginkgo Bioworks (led AI team and corporate development), she serves on boards of Owkin, Bioptimus, Lila Sciences, and others, and advises DARPA. Brings deep expertise in AI-native life sciences to the AI BioHub program.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-02-11
Description

Ajinomoto Co., Inc. (via its subsidiary Ajinomoto Health & Nutrition North America) became a Gold Sponsor of LabCentral and a General Sponsor of LabCentral 238. The sponsorship aligns with Ajinomoto's AminoScience strategy and supports cell and gene therapy innovation. Ajinomoto engages with pioneering biotech entrepreneurs through the LabCentral ecosystem.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-10
Description

A five-year strategic partnership between BioLabs, LabCentral, MBC BioLabs, and AbbVie to foster early-stage innovation across the network. AbbVie sponsors Golden Tickets usable at LabCentral, MBC BioLabs, and BioLabs sites in the US, France, and Germany. Residents gain access to AbbVie Ventures investment, R&D expertise, mentorship, and networking events.

Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2024-11-22
Description

Daiichi Sankyo joined LabCentral as a Platinum Sponsor. Daiichi Sankyo recently introduced the Daiichi Sankyo Research Institute of Boston to collaborate with the local innovation ecosystem and is committed to building deeper partnerships with the Boston community for drug discovery.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioLabs is the most directly comparable peer — a global shared-lab coworking network also co-founded by Johannes Fruehauf. It operates sites across the US, France, Germany, and Japan with the same nonprofit-adjacent sponsor and Golden Ticket model (e.g., shared Servier and AbbVie partnerships). Both serve early-stage biotechs via subscription bench rentals plus sponsor-funded programming.

TypeDirect peer
Description

MBC BioLabs operates shared lab facilities in San Carlos and San Francisco with a model and sponsor overlap (joint AbbVie Golden Ticket partnership) nearly identical to LabCentral's. Targets the same early-stage biotech founder segment with subsidized bench space, equipment access, and pharma-sponsored residency programs.

TypeDirect peer
Description

CIC is a major Cambridge-based coworking and innovation operator that co-hosts AI BioHub participants and provides office space to AI BioHub teams through its partnership with C10 Labs. While broader than biotech, it is a direct comparable in the Kendall Square coworking ecosystem for early-stage science and tech startups.

TypeRegional player
Description

The Engine is an MIT-affiliated tough-tech incubator co-hosting Boston Biotech Investor Day with LabCentral. It serves a partially overlapping resident base of science-based startups in Cambridge, including biotech, with venture funding and lab/office infrastructure similar to LabCentral's offering.

TypeBroad incumbent
Description

Alexandria is the dominant publicly traded REIT focused on Class A life sciences real estate in Kendall Square and the broader Cambridge cluster. LabCentral is an infrastructure tenant and partner of the broader Alexandria-anchored ecosystem, providing the operator/programming layer atop Alexandria-style lab buildings.

TypeBroad incumbent
Description

Alexandria LaunchLabs is Alexandria's own branded coworking/incubator space for early-stage life sciences companies in New York City and Cambridge. It competes for the same early-stage biotech resident pool and offers turnkey lab infrastructure with a different cost structure (for-profit REIT-backed).

7Shonan iPark
TypeDirect peer
Description

Shonan iPark is Japan's first pharmaceutical-initiated science park (backed by Takeda) and LabCentral's partner for a 3-month Cambridge residency exchange. Operates a comparable shared lab and programming model for early-stage biotech startups, but primarily in Japan — making it both a peer and an international channel partner.

TypeBroad incumbent
Description

JLABS is Johnson & Johnson's global network of life sciences incubators offering no-strings-attached lab space, equipment, and programming to early-stage biotech and pharma startups. Operates as a broad incumbent with overlapping value proposition (turnkey lab + sponsor-backed residency) across multiple geographies.

TypeRegional player
Description

QB3 is a University of California-affiliated nonprofit that operates shared lab incubators (e.g., Bakar Labs, StartPad) supporting early-stage life sciences startups. Comparable mission-driven model providing subsidized lab space, equipment access, and entrepreneur support, but concentrated in the San Francisco Bay Area rather than the Northeast.

TypeRegional player
Description

Cure is a New York City-based nonprofit life sciences campus offering shared lab space, programming, and an innovation hub for early-stage biotechs. Operates with a similar nonprofit-plus-sponsor model and targets the same early-stage resident segment, but serves the New York ecosystem rather than Cambridge.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LabCentral

Biotech Lab Infrastructure and Incubator Serviceslabcentral.org

LabCentral is a nonprofit shared laboratory network operating six sites totaling 243,000 square feet in Kendall Square and Harvard, providing lab infrastructure, sponsor-funded programs, and accelerator services to approximately 100 early-stage life sciences and biotech startup teams.

What LabCentral does

LabCentral is a 501(c)(3) nonprofit organization founded in 2013 and headquartered at 700 Main Street in Cambridge, Massachusetts. It operates a six-site network spanning approximately 243,000 square feet across Kendall Square and the Harvard University campus, providing shared, fully permitted laboratory and office infrastructure, shared equipment, and operational support to approximately 100 early-stage life sciences and biotechnology startup teams. Its core products include LabCentral 700 (flagship), LabCentral 238 (process development and scale-up), Bayer Co.Lab Cambridge, and the Harvard-affiliated Pagliuca and Blavatnik Life Labs. LabCentral's revenue comes from three primary streams: month-to-month lab and office rental fees from resident companies, tiered sponsorship payments (Gold, Platinum, General) from pharmaceutical and life sciences companies, and grants from government and nonprofit funders such as the Massachusetts Technology Collaborative.

The organization differentiates itself from a typical coworking operator through a curated ecosystem model. A network of more than 70 sponsor organizations — including Bristol Myers Squibb, Novo Nordisk, Sanofi, Daiichi Sankyo, Takeda, Lilly, Pfizer, Bayer, AbbVie, Ajinomoto, Servier, and Breakthrough T1D — funds programs such as Golden Tickets ($50,000 residency credits), the annual Ignite contest, and LabCentral First (six months of free bench space for first-time founders). LabCentral also runs the AI BioHub, a 2025-launched center of excellence co-developed with C10 Labs that combines wet lab infrastructure with AI-specific resources, a 10-week accelerator curriculum, and mentorship. Resident and alumni companies have cumulatively raised $21.85 billion in venture capital since 2013, catalyzed 7,915 jobs in Massachusetts, launched 171 clinical trials, and received 1,846 patents, with LabCentral-affiliated companies representing 10% of total US early-stage biopharma venture funding and 16% of Massachusetts early-stage funding. Recent strategic moves include international partnerships with Japan's Shonan iPark and Hong Kong's HKSTP, a 2025 CEO transition, and the addition of a Head of Science Strategy role.

LabCentral firmographics

Firmographics
Name
LabCentral
Legal name
Lab Central, Inc.
Website
https://labcentral.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
LabCentral is a nonprofit shared laboratory network operating six sites totaling 243,000 square feet in Kendall Square and Harvard, providing lab infrastructure, sponsor-funded programs, and accelerator services to approximately 100 early-stage life sciences and biotech startup teams.
Ownership category
akta.pro rank

LabCentral industry classification

Industry
Product category
Biotech Lab Infrastructure and Incubator Services
NAICS
Facilities Support Services (5612), Facilities Support Services (56121)
SIC
Laboratory Apparatus & Furniture (3821)
akta.pro primary industry
Lab Furniture, Facilities & Utilities (Benches, Casework, Gas/Water Systems) (HLAGAIAM)
akta.pro secondary industries
Hands-on Science Exploration & Experiments (Lab Kits, Science Clubs) (EDAMABAA), Makerspace, Innovation Lab & Fab Lab Operations (Tools, Safety, Programming) (EDAEAGAI)

Keywords

  • Shared lab facilities
  • Biotech incubator services
  • Life sciences infrastructure
  • Lab coworking space
  • Biotech startup support

Where LabCentral is headquartered

Location

Headquarters

HQ city
Hardwick
HQ country
United States
HQ region
North America

Offices6 records

Markets served

LabCentral business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

  1. Lab and Office Space Rental: LabCentral provides month-to-month, fully functional lab and office spaces, permitting, waste handling, and equipment for biological R&D. Revenue is generated from bench and office rental fees charged to resident companies. Bench rates were reduced by over 25% for 2026 to support the community.
  2. Sponsorship Programs: Pharmaceutical and life sciences companies sponsor LabCentral at Gold, Platinum, and General tiers. Sponsors gain access to the startup ecosystem, Golden Ticket programs, mentorship opportunities, and networking. Notable sponsors include Sanofi (Gold), Daiichi Sankyo (Platinum), Ajinomoto (Gold), Bristol Myers Squibb (Platinum), AbbVie, Takeda, Lilly, Pfizer, and Bayer.
  3. Nonprofit Funding and Grants: As a 501(c)(3) nonprofit, LabCentral receives grant funding from organizations like the Massachusetts Technology Collaborative (MassTech), which provided a $1.9M Sector Spark Grant for the AI BioHub.

Pricing tiers

ModelBillingPrice
FreemiumMulti-year contractLabCentral First - Free 6-month bench for first-time founders
SubscriptionMulti-year contractGolden Ticket - $50,000 credit for residency
SubscriptionMonthlyStandard Lab Bench and Office Space - Reduced 2026 rates

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

LabCentral product offering

Product offering

Core offering

LabCentral operates a six-site network of fully permitted, ready-to-go shared lab and office facilities in Kendall Square, Cambridge and on the Harvard campus, providing month-to-month rental of lab benches and offices to early-stage life sciences and biotech startups. The offering includes shared equipment, permitting and waste handling, operational and facilities support, and access to a curated ecosystem of sponsors, mentors, and peers. Specialized programs layered on top of the physical infrastructure include the AI BioHub accelerator, sponsor-funded Golden Tickets, and the LabCentral First program for first-time founders.

Product overview

LabCentral is a nonprofit organization operating a network of six shared lab and office facilities across Kendall Square in Cambridge, Massachusetts and Harvard University campus, spanning over 243,000 square feet. The portfolio includes LabCentral 700 (flagship main location), LabCentral 238 (process development/scale-up), Bayer Co.Lab Cambridge, Pagliuca Harvard Life Lab, and Blavatnik Harvard Life Lab Longwood. Beyond physical lab space, LabCentral provides a comprehensive ecosystem including the AI BioHub (AI-biotech accelerator with C10 Labs), Golden Tickets ($50,000 sponsor-funded residency credits), LabCentral First (free lab space for first-time founders), Ignite Golden Tickets ($250,000 annual contest), Core Facilities network, Startup Programs, Pathway Programs (What the Heck is Biotech?, Biotech Blend X, Biotech Ready), and Gallery 1832. The organization supports early-stage life sciences companies with lab infrastructure, operational support, programming, and community to accelerate biotech innovation.

Differentiator

Problem solved

Functional benefit

Brands

  • AI BioHub: AI-biotech accelerator program run in partnership with C10 Labs offering labs, curriculum, mentorship, and infrastructure for AI-first biotech startups.
  • LabCentral First
  • Golden Tickets
  • LabCentral 238
  • Bayer Co.Lab Cambridge
  • Pagliuca Harvard Life Lab
  • Blavatnik Harvard Life Lab
  • Loop Program

Products and services

  • LabCentral 700 Main Street LabCentral's flagship site at 700 Main Street in Cambridge, MA, providing month-to-month, fully functional lab and office spaces, permitting, waste handling, and shared equipment for early-stage biotech startup R&D.
  • LabCentral 238 Purpose-built facility at 238 Main Street in Cambridge, MA, designed for process development and scale-up, offering specialized infrastructure for startups advancing from discovery to larger-scale operations.
  • Bayer Co.Lab Cambridge LabCentral-managed facility with programming curated for entrepreneurs and scientists, providing access to Bayer's ecosystem and specialized biotech support.
  • Pagliuca Harvard Life Lab Harvard-affiliated biotech venture facility where Harvard-affiliated startups can access lab space and resources within the Harvard ecosystem.
  • Blavatnik Harvard Life Lab R&D facility for Harvard-affiliated pre-seed and seed ventures, providing specialized lab infrastructure for early-stage life sciences companies.
  • Core Facilities Network Premier network of core facilities providing access to specialized scientific equipment and expertise to amplify resident R&D capabilities.
  • AI BioHub AI-biotech support program providing startups with labs, infrastructure, instrumentation for high-speed cell sorting, automated liquid handling, and network access to integrate artificial intelligence into biological discovery. Includes accelerator program co-led with C10 Labs.
  • AI BioHub Accelerator Program 10-week accelerator program providing AI-specific curriculum (Business of Biotech to Generative AI and ML Ops), wet lab access, AI Fellows mentorship, and individualized industry mentorship for early-stage AI-biotech companies. First cohort of 13 teams raised over $8M collectively.
  • LabCentral First Program offering eligible first-time biotech founders six months of free lab space at a single bench. Targets first-time founders, new arrivals to Massachusetts, or those pursuing underfunded novel areas of science. Up to 18 startups selected competitively.
  • Golden Ticket Program Sponsor-funded residency opportunities providing selected startups with $50,000 in credits toward lab space and services at LabCentral facilities. Awarded by pharma sponsors including Bristol Myers Squibb, Novo Nordisk, Sanofi, Daiichi Sankyo, Takeda, Lilly, Pfizer, Bayer, AbbVie, and Breakthrough T1D.
  • Ignite Golden Ticket Contest Annual Golden Ticket contest awarding five $50,000 tickets totaling $250,000 in value, with winning companies receiving lab space credits plus a one-year fellowship program with expanded access to resources and networks. Co-sponsored by Bayer, Lilly, Pfizer, and Takeda.

Quantifiable outcome

  • $1.25B raised by resident companies in 2025; $21.85B cumulative since 2013
  • +7 more outcomes

Companies that use LabCentral

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles4 records

LabCentral technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature4 records

LabCentral partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, minor and flagship.

  • HKSTP (Hong Kong Science and Technology Parks)coreStrategic or Co-development Partner · 22 June 2026HKSTP signed an MOU with LabCentral for cross-border startup support as part of HKSTP's largest-ever delegation to BIO 2026 in San Diego. The partnership aims to provide Hong Kong biotech startups access to the LabCentral ecosystem and Greater Boston biotech community.
  • CKD PharmminorGTM or Marketing Partner · 20 May 2026CKD Pharm held its 2026 Golden Ticket event at LabCentral in Boston, awarding the sponsorship to Arpelos Biosciences (AI-driven protein engineering for autoimmune diseases). Approximately 50 biotech startups applied, with three finalists competing. The Golden Ticket program serves as CKD Pharm's platform for identifying early-stage innovative technologies.
  • SanofiflagshipGTM or Marketing Partner · 17 February 2026Sanofi joined LabCentral as a Gold Sponsor, hosting their inaugural Golden Ticket reception in January 2026. Sanofi outlined a four-pillar R&D vision (immunoscience, neuroscience, oncology, genomic medicine) and collaborative mechanisms including iAwards, Open Innovation Lab, and startup bridge programs. Sanofi will launch a Golden Ticket program and host office hours with resident startups.
  • Bristol Myers SquibbflagshipGTM or Marketing Partner · 15 October 2025Bristol Myers Squibb sponsors LabCentral's Golden Ticket program as a Platinum Sponsor. BMS evaluates and awards $50,000 credits to early-stage biotech companies working in oncology, immunology, cardiovascular disease, and neuroscience. Deck Bio and ReTrax Therapeutics were awarded 2025 BMS Golden Tickets.
  • Shonan iPark (Japan)coreStrategic or Co-development Partner · 7 October 2025LabCentral partnered with Shonan iPark, Japan's first pharmaceutical-initiated science park, to offer selected Japanese startup teams a three-month residency program in Cambridge. Participants engage in executive educational programming and connect with the LabCentral ecosystem. LabCentral and Shonan iPark also co-host the Shonan Health Innovation Conference (SHIC) 2025 in Cambridge. Operated by iPark Institute Co., Ltd., backed by Takeda, IIF, and Mitsubishi Corporation.
  • BioLabs and The EnginecoreStrategic or Co-development Partner · 4 September 2025LabCentral co-hosts the Boston Biotech Investor Day (BBID) with BioLabs and The Engine, now in its second year (2025). The Termeer Institute joined as a co-host. BBID features 48 early-stage companies, 90+ investors and pharma partners, entrepreneur pitches, and poster presentations. Reinforces Massachusetts as a global life sciences leader.
  • Termeer InstitutecoreStrategic or Co-development Partner · 4 September 2025The Termeer Institute joined as a co-host of Boston Biotech Investor Day 2025. The Termeer Institute empowers a diverse global community of life science innovators, aligning with LabCentral's mission to support the ecosystem around biotech entrepreneurs.
  • Breakthrough T1D (formerly JDRF)coreStrategic or Co-development Partner · 5 August 2025Breakthrough T1D partnered with LabCentral to launch a Golden Ticket competition specifically for companies working to treat or cure type 1 diabetes. The $50,000 award is Earmarked for Disease Modifying Therapies (DMT) and Cell Therapies (CT) in T1D. This is a first-of-its-kind partnership between LabCentral and a mission-driven nonprofit.
  • Bayer, Lilly, Pfizer, Takeda (Ignite Golden Ticket Sponsors)coreGTM or Marketing Partner · 31 July 2025Bayer, Lilly, Pfizer, and Takeda co-sponsor LabCentral's annual Ignite Golden Ticket contest, awarding five $50,000 tickets totaling $250,000. Each winning company also receives a one-year fellowship program with access to resources and networks. The contest is in its fifth year (2025).
  • ServiercoreGTM or Marketing Partner · 28 May 2025Servier expanded its Golden Ticket incubator program globally, partnering with LabCentral in Boston-Cambridge and BioLabs at Saclay in France (Spartners facility). Servier's program offers selected startups one-year incubation, lab facilities, researcher operating costs, and mentorship in oncology and neurology. LabCentral has awarded over 150 Golden Tickets worth $7.5M since 2017.
  • C10 LabscoreStrategic or Co-development Partner · 18 March 2025LabCentral and C10 Labs co-developed the AI BioHub in Kendall Square, a center of excellence for AI-native biotech startups. C10 Labs co-leads multiple AI/bio cohorts, providing AI expertise, fractional AI engineers, cloud infrastructure, and venture studio methodology. The first cohort graduated 13 teams that raised over $8M collectively. The second cohort of 16 teams began in March 2026.
  • Anna Marie Wagner (Strategic Advisor)minorOthers · 18 March 2025Anna Marie Wagner, a leader at the intersection of AI and life sciences, joined LabCentral's AI BioHub as a strategic advisor. Previously an executive at Ginkgo Bioworks (led AI team and corporate development), she serves on boards of Owkin, Bioptimus, Lila Sciences, and others, and advises DARPA. Brings deep expertise in AI-native life sciences to the AI BioHub program.
  • Ajinomoto Health & Nutrition North AmericacoreGTM or Marketing Partner · 11 February 2025Ajinomoto Co., Inc. (via its subsidiary Ajinomoto Health & Nutrition North America) became a Gold Sponsor of LabCentral and a General Sponsor of LabCentral 238. The sponsorship aligns with Ajinomoto's AminoScience strategy and supports cell and gene therapy innovation. Ajinomoto engages with pioneering biotech entrepreneurs through the LabCentral ecosystem.
  • AbbVieflagshipStrategic or Co-development Partner · 10 January 2025A five-year strategic partnership between BioLabs, LabCentral, MBC BioLabs, and AbbVie to foster early-stage innovation across the network. AbbVie sponsors Golden Tickets usable at LabCentral, MBC BioLabs, and BioLabs sites in the US, France, and Germany. Residents gain access to AbbVie Ventures investment, R&D expertise, mentorship, and networking events.
  • Daiichi SankyoflagshipGTM or Marketing Partner · 22 November 2024Daiichi Sankyo joined LabCentral as a Platinum Sponsor. Daiichi Sankyo recently introduced the Daiichi Sankyo Research Institute of Boston to collaborate with the local innovation ecosystem and is committed to building deeper partnerships with the Boston community for drug discovery.

Scale indicators16 records

Recent moves8 records

Expansion highlights6 records

LabCentral competitors and assessment

Company assessment

Direct peers

  • BioLabs: BioLabs is the most directly comparable peer — a global shared-lab coworking network also co-founded by Johannes Fruehauf. It operates sites across the US, France, Germany, and Japan with the same nonprofit-adjacent sponsor and Golden Ticket model (e.g., shared Servier and AbbVie partnerships). Both serve early-stage biotechs via subscription bench rentals plus sponsor-funded programming.
  • MBC BioLabs: MBC BioLabs operates shared lab facilities in San Carlos and San Francisco with a model and sponsor overlap (joint AbbVie Golden Ticket partnership) nearly identical to LabCentral's. Targets the same early-stage biotech founder segment with subsidized bench space, equipment access, and pharma-sponsored residency programs.
  • Cambridge Innovation Center (CIC): CIC is a major Cambridge-based coworking and innovation operator that co-hosts AI BioHub participants and provides office space to AI BioHub teams through its partnership with C10 Labs. While broader than biotech, it is a direct comparable in the Kendall Square coworking ecosystem for early-stage science and tech startups.
  • Shonan iPark: Shonan iPark is Japan's first pharmaceutical-initiated science park (backed by Takeda) and LabCentral's partner for a 3-month Cambridge residency exchange. Operates a comparable shared lab and programming model for early-stage biotech startups, but primarily in Japan — making it both a peer and an international channel partner.

Regional players

  • The Engine (MIT): The Engine is an MIT-affiliated tough-tech incubator co-hosting Boston Biotech Investor Day with LabCentral. It serves a partially overlapping resident base of science-based startups in Cambridge, including biotech, with venture funding and lab/office infrastructure similar to LabCentral's offering.
  • QB3 (California Institute for Quantitative Biosciences): QB3 is a University of California-affiliated nonprofit that operates shared lab incubators (e.g., Bakar Labs, StartPad) supporting early-stage life sciences startups. Comparable mission-driven model providing subsidized lab space, equipment access, and entrepreneur support, but concentrated in the San Francisco Bay Area rather than the Northeast.
  • Cure (NYC life sciences hub): Cure is a New York City-based nonprofit life sciences campus offering shared lab space, programming, and an innovation hub for early-stage biotechs. Operates with a similar nonprofit-plus-sponsor model and targets the same early-stage resident segment, but serves the New York ecosystem rather than Cambridge.

Broad incumbents

  • Alexandria Real Estate Equities: Alexandria is the dominant publicly traded REIT focused on Class A life sciences real estate in Kendall Square and the broader Cambridge cluster. LabCentral is an infrastructure tenant and partner of the broader Alexandria-anchored ecosystem, providing the operator/programming layer atop Alexandria-style lab buildings.
  • Alexandria LaunchLabs: Alexandria LaunchLabs is Alexandria's own branded coworking/incubator space for early-stage life sciences companies in New York City and Cambridge. It competes for the same early-stage biotech resident pool and offers turnkey lab infrastructure with a different cost structure (for-profit REIT-backed).
  • JLABS (Johnson & Johnson Innovation): JLABS is Johnson & Johnson's global network of life sciences incubators offering no-strings-attached lab space, equipment, and programming to early-stage biotech and pharma startups. Operates as a broad incumbent with overlapping value proposition (turnkey lab + sponsor-backed residency) across multiple geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

LabCentral social profiles

Digital presence

LabCentral financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LabCentral leadership team

Management profile

Number of profiles

Profiles4 records

LabCentral funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LabCentral M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LabCentral

What does LabCentral do?

LabCentral operates a six-site network of fully permitted, ready-to-go shared lab and office facilities in Kendall Square, Cambridge and on the Harvard campus, providing month-to-month rental of lab benches and offices to early-stage life sciences and biotech startups. The offering includes shared equipment, permitting and waste handling, operational and facilities support, and access to a curated ecosystem of sponsors, mentors, and peers. Specialized programs layered on top of the physical infrastructure include the AI BioHub accelerator, sponsor-funded Golden Tickets, and the LabCentral First program for first-time founders.

Is LabCentral a public or private company?

LabCentral is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was LabCentral founded?

LabCentral was founded in 2013. It employs 51 to 100 people.

Where is LabCentral based?

LabCentral is headquartered in Hardwick, United States, in the North America region.

How does LabCentral make money?

Three revenue lines are on record. Lab and Office Space Rental is the primary driver. The others are sponsorship Programs and nonprofit Funding and Grants.

Who are LabCentral's main competitors?

Direct peers on record are BioLabs, MBC BioLabs, Cambridge Innovation Center (CIC) and Shonan iPark. Regional players are The Engine (MIT), QB3 (California Institute for Quantitative Biosciences) and Cure (NYC life sciences hub). Broad incumbents are Alexandria Real Estate Equities, Alexandria LaunchLabs and JLABS (Johnson & Johnson Innovation).

Does LabCentral have an API?

No public API is recorded for LabCentral.

What industry is LabCentral in?

LabCentral's product category is Biotech Lab Infrastructure and Incubator Services. Its primary akta.pro industry code is HLAGAIAM, Lab Furniture, Facilities & Utilities (Benches, Casework, Gas/Water Systems), with a secondary code of EDAMABAA, Hands-on Science Exploration & Experiments (Lab Kits, Science Clubs). Its NAICS code is 5612 and its SIC code is 3821.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PlatumThree Seoul bio startups participate in Boston LabCentral's 'The Loop'... First collaboration with Seoul Biohub.Three Seoul bio startups will join LabCentral's 'The Loop' program in Boston from the 15th to 18th, marking the first collaboration between Seoul Biohub and LabCentral. The program includes pitching workshops, patent training, and meetings with global pharma companies like Pfizer and Bayer. The startups were selected through evaluations by Seoul Biohub and LabCentral.Koreatimestest Seoul biotech startups enter Boston pipeline through LabCentralSeoul biotech startups Survivent Biologics, BioMe, and SilicoPharm joined LabCentral's The Loop program in Boston, seeking investors and pharmaceutical partners. The four-day initiative, part of a global network, aims to connect them with companies like Pfizer and Bayer. Seoul plans to link them with the RESI Boston event for further discussions.BioSpaceWith China rising, Hong Kong builds bridge to biotech innovationLabCentral and the Hong Kong Science and Technology Parks Corporation (HKSTP) signed a memorandum of understanding to facilitate collaboration between biotech founders in the U.S. and Hong Kong, aiming to navigate rising geopolitical barriers with China. The partnership seeks to leverage Hong Kong as a strategic hub for dealmaking and clinical trials while maintaining scientific exchange across borders.AInvestAbbott: No impact to Abbott businesses/customers, nor any known exposure to sensitive customer or business information due to LabCentral hackAbbott has confirmed that its businesses and customers experienced no impact from the cyberattack on LabCentral, with no known exposure to sensitive customer or business information as a result of the breach.BioSpaceBIO outshines World Cup as biotech celebrates 50th anniversary with a ‘call to action’At BIO 2026 in San Diego, attendees marked the 50th anniversary of Genentech's founding, with CEO John Crowley emphasizing the need to outcompete China. The industry reported positive momentum, including 18 IPOs and Eli Lilly's $30 billion in acquisitions, while China's rise was a recurring concern.Media-outreachHKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech StrengthThe Hong Kong Science and Technology Parks Corporation (HKSTP) led a record delegation of 41 organizations to BIO 2026 in San Diego, showcasing the region's life and health technology innovations. The event featured strategic partnerships, including an MOU between HKSTP and LabCentral, and commercial collaborations by companies such as Immuno Cure and Zhaoke Ophthalmology. This presence reinforces Hong Kong's position as a major global hub for biotechnology fundraising and innovation.NewsfileHKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech StrengthHKSTP led Hong Kong's largest-ever delegation of 41 park companies, research institutes, and university spin-offs to BIO 2026 in San Diego, doubling the size of the Hong Kong Pavilion from the previous year. Three major strategic partnerships were signed at the event: HKSTP with LabCentral for cross-border startup support, Immuno Cure with OPIS for overseas clinical trial execution, and Zhaoke Ophthalmology with Brazil's Laboratório Teuto for ophthalmology market entry. HKSTP park company Meta Pharmaceuticals won Third Place in the 2026 Biomedical Pitch Competition, reinforcing Hong Kong's position as the world's second-largest biotech fundraising hub.FinancialContent Business PageHKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech StrengthHKSTP led Hong Kong's largest-ever delegation of 41 tech firms, research institutes, and university spin-offs to the BIO International Convention 2026 in San Diego from June 22–25, showcasing the city's life and health technology innovations across AI-enabled biotech, therapeutics, diagnostics, and pharma. Three major strategic partnerships were signed at the event, including MOUs between HKSTP and LabCentral, Zhaoke Ophthalmology and Brazil's Laboratório Teuto, and a collaboration between Immuno Cure and OPIS for clinical trial execution. HKSTP park company Meta Pharmaceuticals also secured Third Place at a concurrent Biomedical Pitch Competition in Boston.FinancialContent Business PageHKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech StrengthHKSTP led Hong Kong's largest-ever delegation of 41 tech firms, institutes, and university spin-offs to BIO 2026 in San Diego from June 22-25, 2026, doubling the Hong Kong Pavilion size from the previous year to showcase AI-enabled biotech, therapeutics, diagnostics, and pharma innovations. Three major strategic partnerships were signed at the event, including MOUs between HKSTP and LabCentral, Immuno Cure and OPIS, and Zhaoke Ophthalmology and Brazil's Laboratório Teuto. HKSTP park company Meta Pharmaceuticals won Third Place at the 2026 Biomedical Pitch Competition in Boston, reinforcing Hong Kong's position as the world's second-largest biotech fundraising hub.Harvard GazetteHarvard Office of Technology DevelopmentHarvard's Office of Technology Development and LabCentral hosted a Guppy Tank event on June 9, 2026, where Trillion Bio pitched its ionic liquid technology for subcutaneous antibody delivery. The technology aims to improve bioavailability from ~60% to near-complete levels, reducing dose requirements and enabling higher concentrations. The event included a panel of investors and a reception.